US Stock MarketDetailed Quotes
MRKR Marker Therapeutics
- 3.7200
- -0.0700-1.85%
Close Nov 12 16:00 ET
- 3.7200
- 0.00000.00%
Post 19:23 ET
33.19MMarket Cap-3179P/E (TTM)
3.7506High3.6000Low11.93KVolume3.6000Open3.7900Pre Close43.48KTurnover0.18%Turnover RatioLossP/E (Static)8.92MShares6.156852wk High3.42P/B25.16MFloat Cap2.437752wk Low--Dividend TTM6.76MShs Float2447.9980Historical High--Div YieldTTM3.97%Amplitude0.6700Historical Low3.6440Avg Price1Lot Size
Marker Therapeutics Stock Forum
Sign in to post a comment
$Marker Therapeutics (MRKR.US)$ its been long enough for company to gather data and present. what do you say?
1
$Marker Therapeutics (MRKR.US)$ my little MRKR woke up! wondering do you have news coming 😊
2
$Marker Therapeutics (MRKR.US)$ Reuters· just
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma
Marker Therapeutics Awarded $2 Million Grant From Nih in Support of Phase 1 Study Investigating MT-601 in Car-Relapsed Patients With Non-Hodgkin’s Lymphoma
$Marker Therapeutics (MRKR.US)$
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nation...
Marker Therapeutics Awarded $2 Million Grant from NIH in Support of Phase 1 Study Investigating MT-601 in CAR-Relapsed Patients with Non-Hodgkin’s Lymphoma
Marker Therapeutics (Nasdaq: MRKR) has been awarded a $2 million grant from the NIH Small Business Innovation Research program to support the clinical investigation of MT-601 in patients with non-Hodgkin's lymphoma (NHL) who have relapsed following anti-CD19 CAR T cell therapy. The grant will fund the nation...
$Marker Therapeutics (MRKR.US)$ All small biotech companies sell shares on good news, why did Marker previously cancel their sale? Does anyone have any ideas or reason?
$Marker Therapeutics (MRKR.US)$ Marker Therapeutics Says 'MultiTAA-specific T Cell Therapies Demonstrate Clinical Safety and Positive Clinical Data Across Multiple Indications'![]()
8
No comment yet
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data
Green Dragon 2024 OP : Let’s say 2 weeks